Pathology of pulmonary arterial hypertension.

The pathological features of pulmonary arterial hypertension are highlighted in this review, which can serve as a guide to diagnosis and identification of potential cellular targets for novel lines of therapy. It also emphasizes the variability of pathological processes found in pulmonary hypertensive lungs collected by the Pulmonary Breakthrough Initiative of the Cardiovascular Medical Research Fund. This initiative is aimed at banking properly phenotyped lung tissue and implementing relevant human lung-based investigations of pulmonary arterial hypertension. This effort has led to an insight of site-specific heterogeneity of relevant pulmonary vascular pathologies and how associated histopathological processes, including interstitial fibrotic and inflammatory findings, may need to be considered in the development of future therapies. We also highlight the pulmonary vascular pathology in schistosomiasis-associated pulmonary arterial hypertension, possibly the most frequent cause of pulmonary hypertension worldwide.

[1]  M. Skokan,et al.  Evidence for cell fusion is absent in vascular lesions associated with pulmonary arterial hypertension. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[2]  G. Butrous,et al.  Pulmonary Vascular Disease in the Developing World , 2008, Circulation.

[3]  M. Yoder,et al.  Lung microvascular endothelium is enriched with progenitor cells that exhibit vasculogenic capacity. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[4]  V. Kurup,et al.  Pulmonary arterial remodeling induced by a Th2 immune response , 2008, The Journal of experimental medicine.

[5]  R. Tuder,et al.  Pathology of pulmonary hypertension. , 2007, Clinics in chest medicine.

[6]  J. Prchal,et al.  Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. , 2007, Blood.

[7]  J. Krishnan,et al.  Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. , 2006, Arthritis and rheumatism.

[8]  N. Voelkel,et al.  Morphologic changes in explanted lungs after prostacyclin therapy for pulmonary hypertension. , 2006, European journal of medical research.

[9]  D. Badesch,et al.  Autoimmunity and pulmonary hypertension: a perspective , 2005, European Respiratory Journal.

[10]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[11]  G. Semenza,et al.  Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis , 2001, The Journal of pathology.

[12]  N. Voelkel,et al.  The pathobiology of pulmonary hypertension. Endothelium. , 2001, Clinics in chest medicine.

[13]  N. Voelkel,et al.  Microsatellite Instability of Endothelial Cell Growth and Apoptosis Genes Within Plexiform Lesions in Primary Pulmonary Hypertension , 2001, Circulation research.

[14]  A. Bogers,et al.  Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease , 2000, The Journal of pathology.

[15]  R. L. Williams,et al.  Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. , 1999, The American journal of pathology.

[16]  S. Rich,et al.  Development of nonspecific interstitial pneumonitis associated with long-term treatment of primary pulmonary hypertension with prostacyclin. , 1999, Chest.

[17]  K. Shroyer,et al.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. , 1998, The Journal of clinical investigation.

[18]  N. Voelkel,et al.  Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. , 1997, Human pathology.

[19]  V. S. Zhdanov,et al.  Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. , 1995, The American journal of pathology.

[20]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[21]  H. Mohri,et al.  Distribution of arterial lesions and collateral pathways in the pulmonary hypertension of congenital heart disease: a computer aided reconstruction study. , 1990, Thorax.

[22]  S. Yousem.  The pulmonary pathologic manifestations of the CREST syndrome. , 1990, Human pathology.

[23]  M. Yacoub,et al.  The histopathology of 36 cases of plexogenic pulmonary arteriopathy , 1990, Histopathology.

[24]  B. Groves,et al.  Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. , 1989, Circulation.

[25]  J. Gosney,et al.  Ultrastructure of early plexogenic pulmonary arteriopathy , 1988, Histopathology.

[26]  D. Heath,et al.  Electron microscopy of the plexiform lesion. , 1979, Thorax.

[27]  K. Horsfield,et al.  Morphometry of the Small Pulmonary Arteries in Man , 1978, Circulation research.

[28]  G Cumming,et al.  Morphometry of the Human Pulmonary Arterial Tree , 1973, Circulation research.

[29]  J. Dobiáš.  Histopathology of pulmonary hypertension. , 1972, Acta Universitatis Carolinae. Medica.

[30]  J. Edwards,et al.  The Pathology of Hypertensive Pulmonary Vascular Disease: A Description of Six Grades of Structural Changes in the Pulmonary Arteries with Special Reference to Congenital Cardiac Septal Defects , 1958, Circulation.